Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PETS
PETS logo

PETS Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.840
Open
1.760
VWAP
1.81
Vol
16.52K
Mkt Cap
39.10M
Low
1.760
Amount
29.90K
EV/EBITDA(TTM)
--
Total Shares
21.37M
EV
17.27M
EV/OCF(TTM)
--
P/S(TTM)
0.21
PetMed Express, Inc., doing business as PetMeds, is a direct-to-consumer pet pharmacy. The Company is an online provider of prescription and non-prescription medications, food, supplements, and supplies and has veterinary and pet insurance service partnerships for dogs, cats, and horses. It markets and sells directly to consumers through their Websites, toll-free numbers, and employer benefit partnerships. Its product line contains over 15,000 SKUs of pet medications, health products, foods, and supplies. The Company offers various pet supplies, including beds, crates, stairs and other pet supplies. Its products include Prescription Medications (Rx), Non-Prescription Medications (OTC) and supplies, Pet Foods, Private Label and Holistic Wellness Services. Rx includes heartworm and flea and ticks preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.
Show More

Events Timeline

(ET)
2026-06-02
19:30:00
Utilities and Basic Materials Propel S&P 500 to New Record Highs
select
2026-06-02
16:30:00
Company Rejects Two Acquisition Proposals, Continues Independent Operations
select
2026-06-02
16:20:00
Company Reports Q4 Revenue of $42.82M
select
2026-04-22 (ET)
2026-04-22
17:00:00
PetMed Express Partners with Rural King for New Pet Pharmacy
select
2026-01-09 (ET)
2026-01-09
08:50:00
BTQ Technologies Corp. Borrow Rate Increases to 18.41%
select
2025-12-16 (ET)
2025-12-16
12:10:00
Cardone Ventures Proposes to Acquire PetMed Express for $4.25 per Share
select
2025-12-11 (ET)
2025-12-11
09:50:00
PetMed Express Receives $4 Acquisition Proposal from SilverCape
select
2025-12-10 (ET)
2025-12-10
08:10:00
PetMeds Unveils New Holiday Collection
select
2025-11-13 (ET)
2025-11-13
08:08:22
PetMed Express announces estimated Q2 revenue between $43.4M and $44.5M
select
2025-10-20 (ET)
2025-10-20
08:41:51
James LaCamp Joins PetMed Express Board of Directors
select

News

Yahoo Finance
9.5
06-03Yahoo Finance
PetMed Express Reports Financial and Operational Improvements
  • Regulatory Compliance Restored: PetMed Express successfully regained critical regulatory compliance and improved internal controls in fiscal year 2026, remediating three previously disclosed material weaknesses, thereby laying a foundation for future sustainable growth.
  • Sales Fluctuations: While the fourth quarter net sales marked the first sequential increase since fiscal year 2024, the overall net sales for the year declined by 21.1%, indicating that the ongoing decrease in prescription medication sales negatively impacted total revenue.
  • Cost Reduction Success: The company exited underperforming vendor relationships, yielding approximately $6.1 million in annualized savings, which not only improved cost structure but also enhanced operational efficiency and customer experience.
  • Clear Strategic Direction: Looking ahead to fiscal year 2027, PetMed Express plans to focus on operational excellence, customer retention, and market expansion, aiming to drive long-term sustainable shareholder value through B2B relationships and improvements in technology and infrastructure.
NASDAQ.COM
2.0
06-03NASDAQ.COM
PetMed Express (PETS) Q4 2026 Earnings Transcript
seekingalpha
9.5
06-02seekingalpha
PetMed Express Q4 Fiscal 2026 Earnings Call Insights
  • Sales Decline: PetMed Express reported net sales of $179 million for fiscal year 2026, reflecting a 21.1% year-over-year decline primarily due to reduced prescription medication sales, although the revenue decline slowed to 15.6% in Q4 compared to the previous year.
  • Cost Reduction Success: The company made significant progress in cost-cutting efforts, exiting underperforming vendor relationships in the second half of the year, which is expected to yield approximately $6.1 million in annualized savings, indicating effective financial management.
  • Technology Infrastructure Upgrade: The successful implementation of a new ERP system, fraud prevention system, and call center technology has strengthened operational capabilities, aiming to enhance customer experience and significantly reduce operational risks moving forward.
  • Independent Operation Decision: The Board opted not to proceed with two unsolicited acquisition proposals priced between $4 and $4.25 per share, choosing to continue operating as an independent publicly traded company, which reflects confidence in the company's long-term strategy.
seekingalpha
9.5
06-02seekingalpha
PetMed Express Reports Wider Loss Amid Revenue Decline
  • Wider Loss Reported: PetMed Express reported a fiscal fourth-quarter loss of $0.19 per share, which, while an improvement from last year's $0.56 loss, still missed expectations by $0.01, indicating ongoing profitability challenges for the company.
  • Significant Revenue Decline: The company's net sales fell by 15.6% to $42.8 million, primarily driven by a decrease in prescription medication sales, a trend that could negatively impact future market share and competitive positioning.
  • Deteriorating Cash Flow: By fiscal year-end, PetMed Express's cash and cash equivalents plummeted nearly two-thirds to $21.4 million, and net cash from operating activities swung to a $28.4 million outflow from a $4.7 million inflow a year earlier, reflecting increasing liquidity risks for the company.
  • Rejection of Acquisition Offers: Despite receiving a $4.25 per share acquisition offer from Cardone Ventures, PetMed Express has opted to continue operating as an independent publicly traded company, a decision that may affect investor confidence in the company's future prospects.
seekingalpha
9.5
06-02seekingalpha
PetMed Express Q4 Earnings Miss Expectations Amid Acquisition Proposals
  • Earnings Report Disappointment: PetMed Express reported a Q4 GAAP EPS of -$0.19, missing expectations by $0.01, indicating ongoing challenges in profitability that may undermine investor confidence.
  • Significant Revenue Decline: The company's Q4 revenue of $42.82 million represents a 15.6% year-over-year decrease, reflecting weak market demand and intensified competition, which could lead to uncertainty in future growth prospects.
  • Acquisition Proposals Rejected: The Board determined it is in the best interest of the company not to proceed with publicly announced acquisition proposals, indicating a commitment to operate as an independent publicly traded entity, which may affect shareholder perceptions of the company's strategic direction.
  • Potential Acquisition Price Range: In December 2025, the company received two unsolicited, non-binding acquisition proposals with offers ranging from $4.00 to $4.25 per share, demonstrating market interest in its assets, although no transactions were finalized.
seekingalpha
9.5
06-02seekingalpha
Major Earnings Reports Expected After Tuesday's Close
  • Earnings Release Companies: Major companies expected to report earnings after Tuesday's close include Palo Alto Networks (PANW), Ulta Beauty (ULTA), GitLab (GTLB), and Yext (YEXT), all of which hold significant market positions in their respective sectors, drawing keen investor interest.
  • Market Reaction Expectations: Given the influence of these companies in cybersecurity, beauty, software development, and digital marketing, the market's reaction to their earnings reports could impact overall investment sentiment in related industries, especially in the current economic climate.
  • Other Earnings Releases: In addition to the major companies, others like PETS and SPWH are also slated to release earnings after Tuesday's close, potentially providing investors with additional market dynamics and investment opportunities.
  • Earnings Season Calendar: Seeking Alpha offers a comprehensive earnings season calendar, allowing investors to access more information to better navigate market trends and make informed investment decisions.

Valuation Metrics

The current forward P/E ratio for Petmed Express Inc (PETS.O) is 16.69, compared to its 5-year average forward P/E of -9.84. For a more detailed relative valuation and DCF analysis to assess Petmed Express Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-9.84
Current PE
16.69
Overvalued PE
97.53
Undervalued PE
-117.20

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
8.79
Current EV/EBITDA
-2.12
Overvalued EV/EBITDA
15.08
Undervalued EV/EBITDA
2.50

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.88
Current PS
0.20
Overvalued PS
1.52
Undervalued PS
0.23

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

what is the best penny stock for tomorrow
Intellectia · 72 candidates
Market Cap: >= 50.00MPrice: $0.10 - $5.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20One Day Rise Prob: >= 60One Day Predict Return: >= 0.0%
Ticker
Name
Market Cap$
top bottom
LU logo
LU
Lufax Holding Ltd
2.31B
AMTX logo
AMTX
Aemetis Inc
98.64M
BLNK logo
BLNK
Blink Charging Co
117.51M
IOVA logo
IOVA
Iovance Biotherapeutics Inc
996.39M
BBD logo
BBD
Banco Bradesco SA
39.45B
WWR logo
WWR
Westwater Resources Inc
126.25M

Whales Holding PETS

O
Oaktop Capital Management II, L.P.
Holding
PETS
+60.79%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Petmed Express Inc (PETS) stock price today?

The current price of PETS is 1.83 USD — it has increased 1.1

What is Petmed Express Inc (PETS)'s business?

PetMed Express, Inc., doing business as PetMeds, is a direct-to-consumer pet pharmacy. The Company is an online provider of prescription and non-prescription medications, food, supplements, and supplies and has veterinary and pet insurance service partnerships for dogs, cats, and horses. It markets and sells directly to consumers through their Websites, toll-free numbers, and employer benefit partnerships. Its product line contains over 15,000 SKUs of pet medications, health products, foods, and supplies. The Company offers various pet supplies, including beds, crates, stairs and other pet supplies. Its products include Prescription Medications (Rx), Non-Prescription Medications (OTC) and supplies, Pet Foods, Private Label and Holistic Wellness Services. Rx includes heartworm and flea and ticks preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.

What is the price predicton of PETS Stock?

Wall Street analysts forecast PETS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PETS is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Petmed Express Inc (PETS)'s revenue for the last quarter?

Petmed Express Inc revenue for the last quarter amounts to 42.82M USD, decreased -7.85

What is Petmed Express Inc (PETS)'s earnings per share (EPS) for the last quarter?

Petmed Express Inc. EPS for the last quarter amounts to -0.19 USD, decreased -66.07

How many employees does Petmed Express Inc (PETS). have?

Petmed Express Inc (PETS) has 189 emplpoyees as of June 24 2026.

What is Petmed Express Inc (PETS) market cap?

Today PETS has the market capitalization of 39.10M USD.